{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:40:25Z","timestamp":1772120425548,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T00:00:00Z","timestamp":1494806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["contemporaryclinicaltrials.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.cct.2017.05.007","type":"journal-article","created":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T14:46:11Z","timestamp":1494254771000},"page":"78-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis"],"prefix":"10.1016","volume":"58","author":[{"given":"Timothy","family":"Aksamit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiemo-Joerg","family":"Bandel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Criollo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"De Soyza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Stuart","family":"Elborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Operschall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Polverino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.cct.2017.05.007_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thx.2010.136119","article-title":"British Thoracic Society guideline for non-CF bronchiectasis","volume":"65","author":"Pasteur","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.cct.2017.05.007_bb0010","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/qjmed\/hct109","article-title":"Non-cystic fibrosis bronchiectasis","volume":"106","author":"McDonnell","year":"2013","journal-title":"Q. J. Med."},{"key":"10.1016\/j.cct.2017.05.007_bb0015","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1164\/rccm.201303-0411CI","article-title":"Non-cystic fibrosis bronchiectasis","volume":"188","author":"McShane","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cct.2017.05.007_bb0020","first-page":"6","article-title":"Inflammation: a two-edged sword \u2013 the model of bronchiectasis","volume":"147","author":"Cole","year":"1986","journal-title":"Eur. J. Respir. Dis. Suppl."},{"key":"10.1016\/j.cct.2017.05.007_bb0025","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1183\/09031936.00119114","article-title":"Management of bronchiectasis in adults","volume":"45","author":"Chalmers","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cct.2017.05.007_bb0030","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.rmed.2010.02.022","article-title":"Trends in bronchiectasis mortality in England and Wales","volume":"104","author":"Roberts","year":"2010","journal-title":"Respir. Med."},{"key":"10.1016\/j.cct.2017.05.007_bb0035","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1183\/09031936.00003709","article-title":"Mortality in bronchiectasis: a long-term study assessing the factors influencing survival","volume":"34","author":"Loebinger","year":"2009","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cct.2017.05.007_bb0040","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study","volume":"47","author":"Quint","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cct.2017.05.007_bb0045","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1164\/ajrccm.156.2.9607083","article-title":"Validation of the St. George's Respiratory Questionnaire in bronchiectasis","volume":"156","author":"Wilson","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cct.2017.05.007_bb0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1465-9921-13-21","article-title":"Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients","volume":"13","author":"Goeminne","year":"2012","journal-title":"Respir. Res."},{"key":"10.1016\/j.cct.2017.05.007_bb0055","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","article-title":"The Bronchiectasis Severity Index. An international derivation and validation study","volume":"189","author":"Chalmers","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cct.2017.05.007_bb0060","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1378\/chest.07-0490","article-title":"Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis","volume":"132","author":"Martinez-Garcia","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.cct.2017.05.007_bb0065","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised, double-blind, placebo-controlled phase III trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.cct.2017.05.007_bb0070","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1183\/09031936.00026313","article-title":"Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score","volume":"43","author":"Martinez-Garcia","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cct.2017.05.007_bb0075","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/thoraxjnl-2012-202893","article-title":"Research priorities in bronchiectasis","volume":"68","author":"De Soyza","year":"2013","journal-title":"Thorax"},{"issue":"Suppl. 56","key":"10.1016\/j.cct.2017.05.007_bb0080","article-title":"Global burden of non-cystic fibrosis bronchiectasis: a simple epidemiological analysis","volume":"40","author":"Polverino","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cct.2017.05.007_bb0085","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1378\/chest.12-1763","article-title":"Phase III randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis","volume":"144","author":"Bilton","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.cct.2017.05.007_bb0090","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/thoraxjnl-2014-205587","article-title":"Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial","volume":"69","author":"Bilton","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.cct.2017.05.007_bb0095","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.201312-2208OC","article-title":"Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection","volume":"189","author":"Haworth","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cct.2017.05.007_bb0100","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1378\/chest.113.5.1329","article-title":"Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I","volume":"113","author":"O'Donnell","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.cct.2017.05.007_bb0105","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1164\/rccm.201404-0638ED","article-title":"Nebulized colistin for non-cystic fibrosis bronchiectasis: d\u00e9j\u00e0 vu all over again?","volume":"189","author":"Metersky","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cct.2017.05.007_bb0110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccm.2015.11.005","article-title":"Using cystic fibrosis therapies for non-cystic fibrosis bronchiectasis","volume":"37","author":"ElMaraachli","year":"2016","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.cct.2017.05.007_bb0115","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","article-title":"A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis","volume":"183","author":"Murray","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cct.2017.05.007_bb0120","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2017.05.007_bb0125","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis. The BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2017.05.007_bb0130","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis. The BLESS randomized controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2017.05.007_bb0135","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/resp.12233","article-title":"Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis","volume":"19","author":"Wu","year":"2014","journal-title":"Respirology"},{"key":"10.1016\/j.cct.2017.05.007_bb0140","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addr.2014.08.013","article-title":"Inhaled antimicrobial therapy \u2013 barriers to effective treatment","volume":"85","author":"Weers","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.cct.2017.05.007_bb0145","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study","volume":"41","author":"Wilson","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cct.2017.05.007_bb0150","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1183\/09031936.00170014","article-title":"COPD-bronchiectasis overlap syndrome","volume":"45","author":"Hurst","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cct.2017.05.007_bb0155","first-page":"A2445","article-title":"Patterns of pharmacotherapy for non-cystic fibrosis bronchiectasis [abstract]","volume":"191","author":"Henkle","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cct.2017.05.007_bb0160","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/thoraxjnl-2013-203739","article-title":"National BTS bronchiectasis audit 2012: is the quality standard being adhered to in adult secondary care?","volume":"69","author":"Hill","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.cct.2017.05.007_bb0165","doi-asserted-by":"crossref","first-page":"e113373","DOI":"10.1371\/journal.pone.0113373","article-title":"Characterization of lung function impairment in adults with bronchiectasis","volume":"9","author":"Guan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cct.2017.05.007_bb0170","first-page":"1602","article-title":"A comprehensive analysis of the impact of Pseudomonas aeruginosa colonisation on prognosis in adult bronchiectasis","volume":"12","author":"Finch","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.cct.2017.05.007_bb0175","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.rmed.2014.07.021","article-title":"Non cystic fibrosis bronchiectasis: a longitudinal retrospective observational study of Pseudomonas persistence and resistance","volume":"109","author":"McDonnell","year":"2014","journal-title":"Respir. Med."},{"key":"10.1016\/j.cct.2017.05.007_bb0180","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis","volume":"186","author":"Chalmers","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cct.2017.05.007_bb0185","first-page":"A2617","article-title":"Baseline demographic profile of subjects of the phase III RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB) [poster]","author":"De Soyza","year":"2015","journal-title":"Eur. Respir. Soc. Congr."},{"key":"10.1016\/j.cct.2017.05.007_bb0190","first-page":"PA155","article-title":"Baseline profiles of patients randomized in RESPIRE 2 trial of Ciprofloxacin Dry Powder for Inhalation (DPI) in non-CF bronchiectasis by pathogen and prior exacerbation rate [poster]","author":"Aksamit","year":"2016","journal-title":"Eur. Respir. Soc. Congr."},{"key":"10.1016\/j.cct.2017.05.007_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2014.10.009","article-title":"Clinical applications of pulmonary delivery of antibiotics","volume":"85","author":"Flume","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.cct.2017.05.007_bb0200","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis","volume":"340","author":"Ramsey","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2017.05.007_bb0205","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJM199306173282403","article-title":"Efficacy of aerosolized tobramycin in patients with cystic fibrosis","volume":"328","author":"Ramsey","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2017.05.007_bb0210","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"Barker","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cct.2017.05.007_bb0215","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2015-000100","article-title":"Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis","author":"Dorkin","year":"2015","journal-title":"BMJ Open Respir. Res."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714416304712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714416304712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T22:25:39Z","timestamp":1535840739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714416304712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":43,"alternative-id":["S1551714416304712"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2017.05.007","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727610064.793551930","asserted-by":"object"}]},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2017.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}